Real-World Safety Analysis of an Intracanalicular Dexamethasone Insert Using the IRIS® Registry (Intelligent Research in Sight)

Robert T Chang MD¹; Srilatha Vantipalli, PhD²; Dina Akasheh, PhD²; Matthew Cheung, PharmD²; Rabia Gurses-Ozden, MD²; Sonya Li³; Meghan Hatfield³; Andrew LaPrise³; Michael Mgabwu, MD^{1,3}; Michael H Goldstein MD²

¹Stanford University, Palo Alto, CA; ²Ocular Therapeutix, Bedford, MA; ³Verana Health, San Francisco, CA

ASCRS ANNUAL MEETING | April 23-26, 2022 | Washington, DC


Disclosures

- **Presenter:** Robert Chang is a consultant for Verana Health.
- **Co-authors:** Srilatha Vantipalli, Dina Akasheh, Matthew Cheung, and Michael H. Goldstein are employees of Ocular Therapeutix. Meghan Hatfield, Andrew LaPrise, Michael Mbagwu, and Sonya Li are employees of Verana Health.
- Funding: This research was supported by Ocular Therapeutix.
- Acknowledgements: Editorial assistance was provided by Cecelia Wall of Wall Medical Writing, LLC and funded by Ocular Therapeutix.

Background

- Topical steroids and NSAIDs are often used to prevent and treat postoperative inflammation and pain following ophthalmic surgery¹
- Intracanalicular Dexamethasone Insert (DEXTENZA)²: Alternative to Topical Steroid Drops
 - Hydrogel-based insert that releases dexamethasone to the ocular surface in a tapered fashion over 30 days
 - Preservative-free
 - Resorbable; no need for removal
 - FDA-approved for the treatment of:
 - Postop ocular inflammation and pain
 - Ocular itching associated with allergic conjunctivitis

Research Question: What is the safety profile of DEX when used in real-world clinical practice?



References: 1. Juthani VV, et al. Cochrane Database Syst Rev. 2017;7(7):CD010516. 2. DEXTENZA [prescribing information]. Bedford, MA; Ocular Therapeutix, Inc.; 2021.

Study Design: Retrospective Analysis using the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)

Objective: To describe real-world safety outcomes of patients who underwent cataract surgery and did or did not receive intracanalicular dexamethasone insert (DEX)



Key Inclusion Criteria

- Underwent cataract surgery^a from June 1, 2019 to March 31, 2021
- Intracanalicular dexamethasone^b used within -2 to +7 days of cataract procedure

Key Exclusion Criteria

- Missing laterality for cataract surgery
- Missing patient demographic information
- Less than 1-month follow-up after cataract surgery
- Mention of dexamethasone intraocular suspension (DEXYCU[®]) in the procedure table


Safety Outcomes

- Incidence of inflammation events, corneal edema, CME, endophthalmitis, epiphora and lacrimal disorders^c
- Intraocular pressure elevations and changes from baseline

^b defined as presence of J-code (J1096), C-code (C9048), CPT code (0356T), NDC number (70382-0204-01, 70382-204-10), or keywords indicated intracanalicular dexamethasone use (eg, "DEXTENZA", "dexamethasone, lacrimal ophthalmic insert", "intracanalicular dexamethasone", "lacrimal dexamethasone insert") in the procedural table ^c identified by the presence of new ICD-10 codes

^a defined as presence of CPT code 66984 or 66982


Study Population



Incidence of Post-Operative Events

The overall incidence of inflammation events post-op was low and comparable between the DEX+ and DEX- cohorts


POSTOPERATIVE SAFETY EVENTS WITHIN 3 MONTHS



Post-Operative Safety Events in Real World vs Clinical Trials

Anterior uveitis and corneal edema were documented less frequently in the real world than observed in clinical trials

COMPARISON OF POSTOPERATIVE SAFETY EVENTS IN DEX CLINICAL TRIALS AND THE IRIS REGISTRY




* Incidences of safety events from DEX Clinical Trials were pooled from one Phase 2 (NCT01666210) and three Phase 3 (NCT02034019, NCT02089113, and NCT02736175) clinical trials in cataract surgery subjects

† Anterior chamber inflammation reported in DEX clinical trials included iritis and iridocyclitis


Intraocular Pressure: No Prior History of Glaucoma

In patients without glaucoma, rates of IOP elevation ≥10 mmHg were comparable between the DEX+ & DEX- cohort and more frequent on post-op day 1



*Baseline IOP calculated as the average of the two most recent IOP assessments up to 6 months pre-index. If only one pre-index assessment is available, that IOP measurement is the baseline IOP. IOP outcomes were consistent between patients with or without glaucoma: rates of IOP elevation ≥10 mmHg in eyes with glaucoma were comparable between both cohorts and more frequent on postop day 1 (data not presented)

IOP: Real-World vs Clinical Trial Data in Patients without Glaucoma



Baseline IOP calculated as the average of the two most recent IOP assessments up to 6 months pre-index. If only one pre-index assessment is available, that IOP measurement is the baseline IOP. Clinical trials of DEX excluded subjects with a history of glaucoma or ocular hypertension

Real World DEXTENZA Safety Conclusions

- Current study is the largest analysis performed on patients treated with intracanalicular dexamethasone insert (N=10,313 eyes)
- Incidences of inflammatory events, corneal edema, CME, endophthalmitis, epiphora, lacrimal disorders dacryocanaliculitis and dacryocystitis in DEX patients were low
 - Real world data shows anterior uveitis and corneal edema were less frequently documented compared to clinical trials
- Percentage of patients with IOP elevations ≥10 mmHg was comparable in DEX+ and DEX- eyes with or without glaucoma
- Real-world data of treatment with DEX in cataract surgery patients can help inform postmarket safety